These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 27318894)
1. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk. Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894 [TBL] [Abstract][Full Text] [Related]
2. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Beuten J; Gelfond JA; Franke JL; Shook S; Johnson-Pais TL; Thompson IM; Leach RJ Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):588-99. PubMed ID: 20086112 [TBL] [Abstract][Full Text] [Related]
3. Prognostic role of genetic biomarkers in clinical progression of prostate cancer. Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Saiz M; Carmona-Saez P; Alvarez JC; Pascual-Geler M; Lorente JA; Cozar JM Exp Mol Med; 2015 Aug; 47(8):e176. PubMed ID: 26251261 [TBL] [Abstract][Full Text] [Related]
4. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Noonan-Wheeler FC; Wu W; Roehl KA; Klim A; Haugen J; Suarez BK; Kibel AS Prostate; 2006 Jan; 66(1):49-56. PubMed ID: 16114055 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ. Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045 [TBL] [Abstract][Full Text] [Related]
7. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Rennert H; Zeigler-Johnson CM; Addya K; Finley MJ; Walker AH; Spangler E; Leonard DG; Wein A; Malkowicz SB; Rebbeck TR Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):949-57. PubMed ID: 15824169 [TBL] [Abstract][Full Text] [Related]
8. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Robbins CM; Hernandez W; Ahaghotu C; Bennett J; Hoke G; Mason T; Pettaway CA; Vijayakumar S; Weinrich S; Furbert-Harris P; Dunston G; Powell IJ; Carpten JD; Kittles RA Prostate; 2008 Dec; 68(16):1790-7. PubMed ID: 18767027 [TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of the principal genes related to prostate cancer: a review. Alvarez-Cubero MJ; Saiz M; Martinez-Gonzalez LJ; Alvarez JC; Lorente JA; Cozar JM Urol Oncol; 2013 Nov; 31(8):1419-29. PubMed ID: 23141781 [TBL] [Abstract][Full Text] [Related]
10. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Maier C; Haeusler J; Herkommer K; Vesovic Z; Hoegel J; Vogel W; Paiss T Br J Cancer; 2005 Mar; 92(6):1159-64. PubMed ID: 15714208 [TBL] [Abstract][Full Text] [Related]
11. Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population. San Francisco IF; Rojas PA; Torres-Estay V; Smalley S; Cerda-Infante J; Montecinos VP; Hurtado C; Godoy AS J Cell Mol Med; 2014 Jan; 18(1):125-33. PubMed ID: 24224612 [TBL] [Abstract][Full Text] [Related]
12. DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Cybulski C; Wokołorczyk D; Jakubowska A; Gliniewicz B; Sikorski A; Huzarski T; Debniak T; Narod SA; Lubiński J Urol Int; 2007; 79(1):44-9. PubMed ID: 17627168 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Rennert H; Zeigler-Johnson C; Mittal RD; Tan YC; Sadowl CM; Edwards J; Finley MJ; Mandhani A; Mital B; Rebbeck TR Urology; 2008 Aug; 72(2):456-60. PubMed ID: 18436282 [TBL] [Abstract][Full Text] [Related]
15. Association between three genetic variants in kallikrein 3 and prostate cancer risk. Ding WH; Ren KW; Yue C; Zou JG; Zuo L; Zhang LF; Bai Y; Okada A; Yasui T; Mi YY Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30413614 [TBL] [Abstract][Full Text] [Related]
16. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer. Hu J; Qiu Z; Zhang L; Cui F Diagn Pathol; 2014 Apr; 9():84. PubMed ID: 24755043 [TBL] [Abstract][Full Text] [Related]
17. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Agalliu I; Leanza SM; Smith L; Trent JM; Carpten JD; Bailey-Wilson JE; Burk RD Prostate; 2010 Nov; 70(15):1716-27. PubMed ID: 20564318 [TBL] [Abstract][Full Text] [Related]
18. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798 [TBL] [Abstract][Full Text] [Related]
19. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. Fesinmeyer MD; Kwon EM; Fu R; Ostrander EA; Stanford JL Prostate; 2011 Oct; 71(14):1538-47. PubMed ID: 21360564 [TBL] [Abstract][Full Text] [Related]
20. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis. Li H; Fei X; Shen Y; Wu Z Adv Clin Exp Med; 2020 Aug; 29(8):1001-1009. PubMed ID: 32869960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]